Andrew Arnold

Image006 6

Dr. Andrew Arnold’s 30-year career in cancer care and research makes him one of the most senior investigators at the Escarpment Cancer Research Institute.  That longevity has given him a poignant perspective on the challenge that remains. “Until we cure absolutely everybody of cancer, we shall need to conduct clinical trials,” he says. Fortunately, the passion that sparked Dr. Arnold’s interest in clinical trials back when he was a young oncologist in England still drives him today. He likes the discipline  of collaborating on clinical trials that are properly conducted and answer important questions.  Dr. Arnold is also proud of Hamilton’s reputation as a centre with high standards in clinical epidemiology and high participation rates in health care research.  It’s one of the reasons that he was drawn to this city in the first place, and why he has been pleased to head the Clinical Trials Department at the Juravinski Cancer Centre over the past five years. For him, ECRI represents an opportunity to create an environment that will encourage discovery in the next generation of cancer specialists and scientists. “It’s tremendously important to support our new investigators,” he says.

Key Publications:

Seow HY , Whelan P , Levine MN , Cowan K , Lysakowski B , Kowaleski B , Snider A , Xu RY , Arnold A. Funding oncology clinical trials: are cooperative group trials sustainable? J Clin Oncol 30, May 2012.

Mukherjee SD, Coombes ME, Levine M, Cosby J, Kowaleski B, Arnold A. A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials. Invest New Drugs. 2010 May 29. [Epub ahead of print] PubMed PMID: 20512397.

Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007 Sep 20;25(27):4278-84. PubMed PMID: 17878480.